PERFOROMIST
LABA NEB
Formoterol fumarate · Mylan Specialty (Viatris)
Active Medication & Mechanism
- Formoterol fumarate LABA20 mcg per 2 mL unit-dose vial
Long-acting beta2-adrenergic agonist with rapid onset of action (~5 minutes). Relaxes bronchial smooth muscle via beta2-receptor activation and increased intracellular cAMP.
FDA-Approved Dosing by Indication
// approval varies by strength + age COPD
1/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 20 mcg/2 mL | Adults (≥18 years) | 1 vial (20 mcg) nebulized twice daily (morning and evening, ~12 hours apart) Long-term maintenance treatment of bronchoconstriction in COPD, including chronic bronchitis and emphysema. Maximum daily dose is 40 mcg. | 40 mcg | FDA Approved |
Asthma
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | All patients | — | — | Not Approved Perforomist is NOT indicated for asthma. LABA monotherapy in asthma increases risk of serious asthma-related events. |
Acute Use
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Acute bronchospasm / rescue | — | — | Not Approved Not for acute deterioration of COPD. Use a SABA. |